Gerresheimer AG/€GXI
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Gerresheimer AG
**Gerresheimer AG (GXI)** is a leading global partner to the pharma, biotech, and healthcare industries, known for its expertise in manufacturing highly specialized products for medical applications. The company's core business centers around the production of glass and plastic packaging products, including vials, ampoules, cartridges, bottles, and containers used primarily for drug delivery, as well as medical devices, such as insulin pens and inhalers. Founded in 1864, Gerresheimer has established a substantial presence with manufacturing facilities across Europe, the Americas, and Asia, positioning itself as a critical supplier to pharmaceutical and healthcare companies worldwide. Headquartered in Düsseldorf, Germany, Gerresheimer is listed on the Frankfurt Stock Exchange under the ticker symbol GXI. The company leverages its deep industry expertise and global production capabilities to offer innovative solutions and ensure high-quality standards, cementing its competitive edge in the healthcare packaging market.
Ticker
€GXI
Sector
Primary listing
XETRA
Industry
Life Sciences Tools & Services
Headquarters
Employees
13,632
ISIN
DE000A0LD6E6
Website
Gerresheimer AG Metrics
BasicAdvanced
€1.7B
21.14
€2.28
0.81
€0.04
0.08%
Price and volume
Market cap
€1.7B
Beta
0.81
52-week high
€107.91
52-week low
€42.48
Average daily volume
318K
Dividend rate
€0.04
Financial strength
Current ratio
0.608
Quick ratio
0.262
Long term debt to equity
59.373
Total debt to equity
148.286
Dividend payout ratio (TTM)
53.29%
Interest coverage (TTM)
2.23%
Profitability
EBITDA (TTM)
396.291
Gross margin (TTM)
28.95%
Net profit margin (TTM)
3.77%
Operating margin (TTM)
9.58%
Effective tax rate (TTM)
19.52%
Revenue per employee (TTM)
€150,000
Management effectiveness
Return on assets (TTM)
3.01%
Return on equity (TTM)
5.42%
Valuation
Price to earnings (TTM)
21.141
Price to revenue (TTM)
0.796
Price to book
1.1
Price to tangible book (TTM)
-6.15
Price to free cash flow (TTM)
-3.028
Free cash flow yield (TTM)
-33.02%
Free cash flow per share (TTM)
-1,590.80%
Dividend yield (TTM)
0.08%
Forward dividend yield
0.08%
Growth
Revenue change (TTM)
4.55%
Earnings per share change (TTM)
-33.60%
3-year revenue growth (CAGR)
10.10%
10-year revenue growth (CAGR)
4.91%
3-year earnings per share growth (CAGR)
-5.74%
10-year earnings per share growth (CAGR)
0.45%
3-year dividend per share growth (CAGR)
-68.25%
10-year dividend per share growth (CAGR)
-25.41%
Bulls say / Bears say
Gerresheimer's strategic focus on containment solutions and drug delivery systems for biologics, including GLP-1 obesity drugs like Wegovy, positions the company to benefit from the growing demand in this sector. (reuters.com)
Despite recent challenges, Gerresheimer's reaffirmation of its 2025 guidance and expectations for stronger performance in the second half of the year indicate potential for recovery and growth. (reuters.com)
The company's acquisition of Bormioli Pharma and the creation of a new molded glass business unit could enhance its market position and product offerings, potentially driving future revenue growth. (reuters.com)
Gerresheimer's recent downgrade of its 2025 revenue and profit margin outlook due to weakened demand in the cosmetics and liquid medications markets raises concerns about its near-term financial performance. (reuters.com)
The company's decision to slash its 2024 dividend from €1.25 to €0.04 per share to preserve financial flexibility may signal underlying financial strains and could deter income-focused investors. (reuters.com)
The withdrawal of KKR from the private equity consortium considering a takeover of Gerresheimer, leading to a significant share price decline, reflects potential investor skepticism about the company's valuation and future prospects. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gerresheimer AG stock?
Gerresheimer AG (GXI) has a market cap of €1.7B as of June 30, 2025.
What is the P/E ratio for Gerresheimer AG stock?
The price to earnings (P/E) ratio for Gerresheimer AG (GXI) stock is 21.14 as of June 30, 2025.
Does Gerresheimer AG stock pay dividends?
Yes, the Gerresheimer AG (GXI) stock pays dividends to shareholders. As of June 30, 2025, the dividend rate is €0.04 and the yield is 0.08%. Gerresheimer AG has a payout ratio of 53.29% on a trailing twelve-month basis.
When is the next Gerresheimer AG dividend payment date?
The next Gerresheimer AG (GXI) dividend payment date is unconfirmed.
What is the beta indicator for Gerresheimer AG?
Gerresheimer AG (GXI) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.